  To study the response of clinical variables ( HbA We included people aged â‰¥ 18 years with Type 2 diabetes mellitus that initiated liraglutide treatment between November 2011 and May 2015. Demographic and clinical data were retrieved retrospectively over 24 months from electronic medical records with a median duration of observation of 7.0 ( IQR 3.0-12.0) months. Individuals that initiated liraglutide therapy were obese ( BMI 39.1 kg/m In this real-world study , we showed the effectiveness of liraglutide in improving body<symptom> weight , HbA